Aardvark Therapeutics Inc (AARD)

Currency in USD
13.47
-0.11(-0.81%)
Real-time Data·
AARD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
AARD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.3113.60
52 wk Range
4.8819.58
Key Statistics
Prev. Close
13.58
Open
13.32
Day's Range
13.31-13.6
52 wk Range
4.88-19.58
Volume
6.22K
Average Volume (3m)
60.41K
1-Year Change
-
Book Value / Share
6.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AARD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.00
Upside
+144.99%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Aardvark Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Aardvark Therapeutics Inc Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Compare AARD to Peers and Sector

Metrics to compare
AARD
Peers
Sector
Relationship
P/E Ratio
−10.6x−0.2x−0.5x
PEG Ratio
0.09−0.010.00
Price/Book
2.0x0.0x2.6x
Price / LTM Sales
-0.9x3.2x
Upside (Analyst Target)
113.5%170.9%41.2%
Fair Value Upside
Unlock13.5%6.2%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 33.00
(+144.99% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.71 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AARD Income Statement

People Also Watch

2.33
CIGL
-15.58%
3.795
PRME
-7.21%
3.61
CRML
-11.00%
61.915
CDTX
-1.22%
42.17
APOG
-1.43%

FAQ

What Stock Exchange Does Aardvark Therapeutics Trade On?

Aardvark Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Aardvark Therapeutics?

The stock symbol for Aardvark Therapeutics is "AARD."

What Is the Aardvark Therapeutics Market Cap?

As of today, Aardvark Therapeutics market cap is 294.63M.

What Is Aardvark Therapeutics's Earnings Per Share (TTM)?

The Aardvark Therapeutics EPS (TTM) is -4.40.

When Is the Next Aardvark Therapeutics Earnings Date?

Aardvark Therapeutics will release its next earnings report on 02 Sept 2025.

From a Technical Analysis Perspective, Is AARD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Aardvark Therapeutics Stock Split?

Aardvark Therapeutics has split 0 times.

How Many Employees Does Aardvark Therapeutics Have?

Aardvark Therapeutics has 26 employees.

What is the current trading status of Aardvark Therapeutics (AARD)?

As of 29 Jul 2025, Aardvark Therapeutics (AARD) is trading at a price of 13.47, with a previous close of 13.58. The stock has fluctuated within a day range of 13.31 to 13.60, while its 52-week range spans from 4.88 to 19.58.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.